Press releases

16 March, 2021

Abliva reports completion of KL1333 Phase 1a/b study

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced the completion ...

12 January, 2021

Abliva Announces Termination of License Agreement with Fortify Therapeutics

Abliva AB (Nasdaq Stockholm: ABLI) today announced that the license agreement with Fortify Therapeutics, a wholly-owned subsidiary of BridgeBio, regarding a development of a local treatment for Leber’ ...

17 November, 2020

Abliva receives positive regulatory feedback from UK MHRA on KL1333 Phase II/III study plan

10 November, 2020

Abliva initiates a drug-drug interaction study and paves the way for a KL1333 pivotal study in 2021

8 October, 2020

Regulatory

Magnus Persson leaves the Board of Directors of Abliva AB to focus on role as founding partner at Eir Ventures

Abliva AB (Nasdaq Stockholm: ABLI) today announces that Magnus Persson is leaving the company's Board of Directors at his own request, to focus on his role as founding Partner at Eir Ventures, a recen ...

7 October, 2020

Abliva doses the first patient in its KL1333 Phase Ia/b clinical study

Abliva AB (Nasdaq Stockholm: ABLI) today announced that the first primary mitochondrial disease patient in the company’s ongoing KL1333 Phase Ia/b study has been dosed. In this third part of the study ...

16 September, 2020

Abliva’s Mitochondria Day – today at 2 p.m. – 4 p.m. CEST

Abliva AB (Nasdaq Stockholm: ABLI) welcomes, on the occasion of The World Mitochondrial Disease Week, to its virtual Mitochondria Day 2020, today on 16 September at 2 p.m. – 4 p.m. CEST. The purpose o ...

9 September, 2020

Regulatory

Abliva

Press releases

Abliva reports completion of KL1333 Phase 1a/b study

Abliva Announces Termination of License Agreement with Fortify Therapeutics

Abliva receives positive regulatory feedback from UK MHRA on KL1333 Phase II/III study plan

Abliva initiates a drug-drug interaction study and paves the way for a KL1333 pivotal study in 2021

Magnus Persson leaves the Board of Directors of Abliva AB to focus on role as founding partner at Eir Ventures

Abliva doses the first patient in its KL1333 Phase Ia/b clinical study

Abliva’s Mitochondria Day – today at 2 p.m. – 4 p.m. CEST

Abliva intends to start a pivotal KL1333 study second half 2021

Abliva arranges Mitochondria Day on 16 September 2020 – preliminary program

Abliva arranges Mitochondria Day on 16 September 2020

Abliva receives positive FDA feedback on its KL1333 development plan

NeuroVive Pharmaceutical changes its name to Abliva